ISA101, the lead product of ISA Pharmaceuticals, is a synthetic long peptide (SLP??) vaccine for the treatment of human papilloma virus type 16 (HPV16) induced diseases, including cervical cancer, most ano-genital premalignant and malignant lesions, and head and neck cancer.